Subsidiary Series A financing disclosed by Medirom (NASDAQ: MRM) stock

Rhea-AI Filing Summary

Medirom Healthcare Technologies Inc. submitted a Form 6-K as a foreign private issuer to furnish a press release dated October 9, 2025. The press release relates to the Series A equity financing round of its subsidiary, MEDIROM MOTHER Labs Inc.

The Form 6-K clarifies that the information, including the attached press release as Exhibit 99.1, is being furnished rather than filed for liability purposes under the U.S. securities laws and will only be incorporated into other filings if specifically referenced.

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

Commission File Number 001-39809

MEDIROM HEALTHCARE TECHNOLOGIES INC.

(Translation of registrant’s name into English)

2-3-1 Daiba, Minato-ku

Tokyo 135-0091, Japan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

​

​

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Issuance of Press Release

On October 9, 2025, MEDIROM Healthcare Technologies Inc. (the “Company”) issued a press release relating to the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of the Company.

The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.

​

EXHIBIT INDEX

​

Exhibit No.		Description
99.1	​	Press release of the Company

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​	MEDIROM HEALTHCARE TECHNOLOGIES INC.
Date: October 9, 2025	​
​	By:	/s/ Fumitoshi Fujiwara
​	​	Name: Fumitoshi Fujiwara
​	​	Title: Chief Financial Officer

​

FAQ

What did Medirom (MRM) report in this Form 6-K?

The company furnished a press release about the Series A equity financing round of its subsidiary, MEDIROM MOTHER Labs Inc..

Which subsidiary of Medirom (MRM) is involved in the Series A equity financing?

The Series A equity financing round concerns MEDIROM MOTHER Labs Inc., a subsidiary of Medirom Healthcare Technologies Inc.

How is the information in Medirom’s Form 6-K treated under U.S. securities laws?

The information is designated as furnished, not filed, so it is not automatically subject to Section 18 liability or incorporated into other filings unless specifically referenced.

What exhibit is attached to Medirom’s Form 6-K for October 2025?

The Form 6-K includes Exhibit 99.1, which is the press release relating to the Series A equity financing round of MEDIROM MOTHER Labs Inc.

Who signed Medirom’s October 2025 Form 6-K?

The report was signed on behalf of the company by Fumitoshi Fujiwara, Chief Financial Officer.